Cytotoxicity of TAK-1 to leukemia and lymphoma cell lines
| Target Cells . | HLA-A24 . | WT1/ GAPDH* . | % Specific Lysis† . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| Leukemia cell lines | |||||
| TK91 | + | 0.31 | 46.2 | 32.8 | 24.6 |
| MEG01 | + | 0.45 | 52.6 | 40.1 | 28.7 |
| SAS527 | + | 0.18 | 39.2 | 22.4 | 14.1 |
| KH88 | + | 0.57 | 40.5 | 30.8 | 18.3 |
| KAZZ | + | 0.31 | 41.0 | 29.4 | 15.8 |
| KCL-22 | + | 0.33 | 33.0 | 22.0 | 12.4 |
| OUN-1 | + | 0.40 | 47.4 | 34.1 | 20.1 |
| CMK11-5 | + | 0.23 | 36.4 | 27.8 | 18.7 |
| KU812 | − | 0.29 | 0.7 | 0.8 | 0.2 |
| J-111 | − | 0.26 | 0.1 | 0.5 | 0.9 |
| NB4 | − | 0.44 | 2.4 | 2.2 | 2.7 |
| HEL | − | 0.13 | 0.2 | 0.1 | 0 |
| KG-1 | − | 0.40 | 3.1 | 1.6 | 1.9 |
| GANMO-1 | − | 0.21 | 0.2 | 0.1 | 0.7 |
| KT-1 | − | 0.57 | 0.3 | 0.4 | 0.2 |
| MZ93 | − | 0.15 | 1.7 | 1.4 | 1.7 |
| YS-1 | − | 0.34 | 2.4 | 0.7 | 0.4 |
| K562 | − | 0.42 | 0.1 | 0.9 | 0.3 |
| CEM | − | 0.49 | 0.4 | 0.6 | 0.1 |
| Jurkat | − | 0.04 | 1.3 | 1.3 | 1.3 |
| Lymphoma cell lines | |||||
| NAK | + | <0.01 | 1.0 | 1.4 | 1.1 |
| NIS | + | <0.01 | 0.3 | 0.1 | 0.4 |
| KUB | + | <0.01 | 0.2 | 1.0 | 0.7 |
| IZU | + | <0.01 | 2.0 | 1.8 | 1.4 |
| KAW | + | <0.01 | 1.6 | 0.8 | 0.4 |
| IKE | − | <0.01 | 1.0 | 0.4 | 1.1 |
| TKC | − | <0.01 | 0.3 | 0.5 | 1.0 |
| Raji | − | <0.01 | 0.4 | 0.3 | 0.3 |
| Daudi | − | <0.01 | 0 | 0.3 | 1.0 |
| Target Cells . | HLA-A24 . | WT1/ GAPDH* . | % Specific Lysis† . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| Leukemia cell lines | |||||
| TK91 | + | 0.31 | 46.2 | 32.8 | 24.6 |
| MEG01 | + | 0.45 | 52.6 | 40.1 | 28.7 |
| SAS527 | + | 0.18 | 39.2 | 22.4 | 14.1 |
| KH88 | + | 0.57 | 40.5 | 30.8 | 18.3 |
| KAZZ | + | 0.31 | 41.0 | 29.4 | 15.8 |
| KCL-22 | + | 0.33 | 33.0 | 22.0 | 12.4 |
| OUN-1 | + | 0.40 | 47.4 | 34.1 | 20.1 |
| CMK11-5 | + | 0.23 | 36.4 | 27.8 | 18.7 |
| KU812 | − | 0.29 | 0.7 | 0.8 | 0.2 |
| J-111 | − | 0.26 | 0.1 | 0.5 | 0.9 |
| NB4 | − | 0.44 | 2.4 | 2.2 | 2.7 |
| HEL | − | 0.13 | 0.2 | 0.1 | 0 |
| KG-1 | − | 0.40 | 3.1 | 1.6 | 1.9 |
| GANMO-1 | − | 0.21 | 0.2 | 0.1 | 0.7 |
| KT-1 | − | 0.57 | 0.3 | 0.4 | 0.2 |
| MZ93 | − | 0.15 | 1.7 | 1.4 | 1.7 |
| YS-1 | − | 0.34 | 2.4 | 0.7 | 0.4 |
| K562 | − | 0.42 | 0.1 | 0.9 | 0.3 |
| CEM | − | 0.49 | 0.4 | 0.6 | 0.1 |
| Jurkat | − | 0.04 | 1.3 | 1.3 | 1.3 |
| Lymphoma cell lines | |||||
| NAK | + | <0.01 | 1.0 | 1.4 | 1.1 |
| NIS | + | <0.01 | 0.3 | 0.1 | 0.4 |
| KUB | + | <0.01 | 0.2 | 1.0 | 0.7 |
| IZU | + | <0.01 | 2.0 | 1.8 | 1.4 |
| KAW | + | <0.01 | 1.6 | 0.8 | 0.4 |
| IKE | − | <0.01 | 1.0 | 0.4 | 1.1 |
| TKC | − | <0.01 | 0.3 | 0.5 | 1.0 |
| Raji | − | <0.01 | 0.4 | 0.3 | 0.3 |
| Daudi | − | <0.01 | 0 | 0.3 | 1.0 |
The WT1 mRNA expression levels are expressed as WT1 mRNA/GAPDH mRNA intensity ratios quantified by densitometric analysis.
The cytotoxicity of TAK-1 to various leukemia and lymphoma cell lines in the absence of the WT1-peptide was determined by 4-hour51Cr release assays at E:T ratios of 10:1, 5:1, and 2.5:1.